- Home
- PBYI vs CDXS Comparison
PBYI vs CDXS Comparison
Compare PBYI & CDXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PBYI
- CDXS
- Stock Information
- Founded
- PBYI 2010
- CDXS 2002
- Country
- PBYI United States
- CDXS United States
- Employees
- PBYI N/A
- CDXS N/A
- Industry
- PBYI Biotechnology: Pharmaceutical Preparations
- CDXS Major Chemicals
- Sector
- PBYI Health Care
- CDXS Industrials
- Exchange
- PBYI Nasdaq
- CDXS Nasdaq
- Market Cap
- PBYI 263.4M
- CDXS 216.6M
- IPO Year
- PBYI N/A
- CDXS 2010
- Fundamental
- Price
- PBYI $4.95
- CDXS $2.15
- Analyst Decision
- PBYI Strong Buy
- CDXS Buy
- Analyst Count
- PBYI 1
- CDXS 2
- Target Price
- PBYI $7.00
- CDXS $11.00
- AVG Volume (30 Days)
- PBYI 418.9K
- CDXS 656.9K
- Earning Date
- PBYI 11-06-2025
- CDXS 11-06-2025
- Dividend Yield
- PBYI N/A
- CDXS N/A
- EPS Growth
- PBYI 434.29
- CDXS N/A
- EPS
- PBYI 0.97
- CDXS N/A
- Revenue
- PBYI $238,062,000.00
- CDXS $57,164,000.00
- Revenue This Year
- PBYI N/A
- CDXS $12.88
- Revenue Next Year
- PBYI N/A
- CDXS $21.64
- P/E Ratio
- PBYI $5.08
- CDXS N/A
- Revenue Growth
- PBYI 8.63
- CDXS N/A
- 52 Week Low
- PBYI $2.32
- CDXS $1.90
- 52 Week High
- PBYI $6.07
- CDXS $6.08
- Technical
- Relative Strength Index (RSI)
- PBYI 45.94
- CDXS 32.28
- Support Level
- PBYI $5.14
- CDXS $2.52
- Resistance Level
- PBYI $5.52
- CDXS $2.80
- Average True Range (ATR)
- PBYI 0.25
- CDXS 0.14
- MACD
- PBYI -0.06
- CDXS -0.05
- Stochastic Oscillator
- PBYI 17.82
- CDXS 5.80
About PBYI Puma Biotechnology Inc
Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes inventive products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also it develops alisertib. Alisertib is a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis resulting into apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.
About CDXS Codexis Inc.
Codexis Inc is a provider of enzymatic solutions for efficient and scalable therapeutics manufacturing that leverages its proprietary CodeEvolver technology platform to discover, develop, and enhance novel, high-performance enzymes. Codexis enzymes solve challenges associated with small molecule pharmaceuticals manufacturing and nucleic acid synthesis. The Company is currently developing its proprietary ECO Synthesis manufacturing platform to enable the scaled manufacture of RNAi therapeutics through an enzymatic route. Codexis' enzymes can drive improvements such as higher yields, reduced energy usage and waste generation, improved efficiency in manufacturing and greater sensitivity in genomic and diagnostic applications. Geographically, it derives maximum revenue from the Americas.